VedaBio has entered a non-exclusive licensing agreement with Mammoth Biosciences to enhance its CRISPR-based molecular detection platform for diagnostic purposes.
This collaboration grants VedaBio access to key CRISPR intellectual property, which is expected to expedite the development of tailored diagnostic solutions.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The partnership is part of VedaBio’s strategy to create an advanced platform prioritising speed and accuracy, particularly in decentralised healthcare environments.
Mammoth Biosciences co-founder and CTO Janice Chen said: “Mammoth’s vision for diagnostics is to enable new solutions that have a high impact on patient care.
“The combination of Mammoth’s deep CRISPR intellectual property with VedaBio’s unique approach and product vision is an opportunity to deliver on the potential of CRISPR-based diagnostics.”
The integration of CRISPR technology into VedaBio’s existing platform is anticipated to facilitate precise molecular detection.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis advancement is expected to enable rapid and accurate diagnostic capabilities suitable for urgent care facilities, outpatient clinics, and other non-centralised healthcare settings while maintaining high levels of sensitivity and specificity.
VedaBio president and CEO Frederic Sweeney said: “We’re thrilled to work with the Mammoth team to help bring the full promise of CRISPR-based diagnostics to market.
“This initiative expands the avenues for our proprietary platform and allows us to develop highly targeted, amplification-free molecular tests designed for real-world clinical needs.”
In 2023, VedaBio emerged from stealth mode with more than $40m in initial funding led by OMX Ventures, aiming to revolutionise molecular detection.
The company introduced CRISPR Cascade, a platform capable of detecting genetic code without target amplification, which is typically required in methods such as polymerase chain reaction (PCR) to increase nucleic acid copies for detection.
